– According to Nandini Piramal, Piramal Pharma expands its injectables portfolio. – Key new products include Chlorpromazine Hydrochloride and Edaravone for ALS. – The complex hospital generics business grew 14%, driven largely by inhalation anaesthetics. – Reports indicate that the CDMO division experienced an 18% growth in FY25 first nine months.
Key Highlights
– According to chairperson Nandini Piramal, Piramal Pharma plans to expand its injectables portfolio to enhance its critical care business.
– The company has recently launched Chlorpromazine Hydrochloride for psychiatric disorders and is set to introduce more injectables in 2024, including Edaravone for ALS.
– The complex hospital generics division reported a 14% revenue increase year-on-year, primarily due to its inhalation anaesthesia market share.
– Reports indicate that the company’s contract development and manufacturing (CDMO) division has seen an 18% growth in the first nine months of FY25.
Piramal Pharma Ltd is strategically focusing on expanding its portfolio of injectables to bolster its critical care segment, as stated by chairperson Nandini Piramal. The company recently introduced Chlorpromazine Hydrochloride in the US and is preparing for further launches, which include Edaravone injection, specifically targeting amyotrophic lateral sclerosis (ALS). According to Piramal, new additions will enhance the existing lineup of injectables, contributing to overall growth in inhalation anaesthetics and other complex generics products.
The company has shown significant growth in its complex hospital generics sector, noting a 14% rise in revenues, driven by strong sales within its inhalation anaesthesia range. Reports reveal that Piramal is a leading provider of Sevoflurane, capturing over 40% of the US market. The market for Sevoflurane is notable for its effectiveness and minimal environmental impact, contributing to its dominance in the inhalation anaesthesia sector. Reports from brokerage JM Financial highlight the business’s lucrative nature, with margins estimated at 25-30%.
In addition to its strong performance in hospital generics, Piramal Pharma’s CDMO business reported an 18% year-on-year growth in FY25’s first nine months, reflecting continued demand in both commercial and generic API sectors. The company has also invested substantially in expanding its manufacturing capabilities in the United States, preparing for potential industry shifts. According to Piramal, this CDMO segment is expected to drive healthy margins and overall revenue growth across its operations.
For the third quarter, Piramal’s overall revenue growth reached 12.54%, totaling ₹2,204.22 crore. Despite a significant decline in profit due to various market pressures, EBITDA margins remained stable at 16%. Analysts forecast the company will achieve revenues of $2 billion with a 25% EBITDA margin by FY30, highlighting a strong growth trajectory.
Piramal Pharma is actively expanding its injectables portfolio to elevate its critical care business while maintaining a strong presence in inhaled anaesthetics. The company is witnessing solid growth in its complex generics and contract development sectors. Its focused investments and strategic product launches position it well for future revenue increases and market leadership in critical care products.
Original Source: www.livemint.com
Leave a Reply